Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Clinical Study of L-DOS47 in Combination with Doxorubicin for the Treatment of Metastatic Pancreatic Cancer

Trial Profile

A Phase I/II Clinical Study of L-DOS47 in Combination with Doxorubicin for the Treatment of Metastatic Pancreatic Cancer

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin (Primary) ; L-DOS 47 (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Helix BioPharma
  • Most Recent Events

    • 25 Oct 2019 According to a Helix BioPharma media release, the company expects to start enrolling patients starting December 2019.
    • 07 Aug 2019 According to a Helix BioPharma media release, the company has received approval from the U.S. Food and Drug Administration (FDA) to initiate this trial.The company team is already hard at work to begin all the necessary preparatory activities to move the trial forward and look forward to be ready to dose patients at the earliest opportunity.
    • 09 Jul 2019 According to a Helix BioPharma media release, the company has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for approval to initiate this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top